Why the study?
Does benznidazole reduce the composite of death, cardiac arrest, sustained ventricular tachycardia, pacemaker/ICD insertion, cardiac transplantation, new heart failure, stroke, or other thromboembolic event in patients with established Chagas' cardiomyopathy?
Does benznidazole reduce the composite of death, cardiac arrest, sustained ventricular tachycardia, pacemaker/ICD insertion, cardiac transplantation, new heart failure, stroke, or other thromboembolic event in patients with established Chagas' cardiomyopathy?
In patients with established Chagas' cardiomyopathy, benznidazole therapy significantly reduced serum parasite detection but did not improve clinical outcomes over a mean follow-up of 5.4 years.
No takes yet. Share an insight, caveat, or question.
Benznidazole confers no clinical benefit in established Chagas' cardiomyopathy; challenges parasite eradication as a strategy to improve outcomes.
Morillo et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: